<DOC>
	<DOCNO>NCT00268450</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , gemcitabine , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving combination chemotherapy together bevacizumab surgery may make tumor small reduce amount normal tissue need remove . Giving treatment surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give cisplatin , bevacizumab , gemcitabine follow surgery , bevacizumab , paclitaxel work treat patient locally advance nonmetastatic bladder cancer remove surgery .</brief_summary>
	<brief_title>Cisplatin , Bevacizumab , Gemcitabine Followed Surgery , Bevacizumab , Paclitaxel Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pT0 status ( pathologic complete remission rate , evidence disease cystectomy specimen ) patient muscle-invasive , resectable , nonmetastatic transitional cell carcinoma ( TCC ) bladder treat neoadjuvant cisplatin , bevacizumab , gemcitabine hydrochloride follow radical cystectomy adjuvant bevacizumab paclitaxel . Secondary - Determine urinary survivin urocytogenetics predict response patient muscle invasive , resectable , non-metastatic TCC bladder treat neoadjuvant cisplatin gemcitabine chemotherapy bevacizumab . - Evaluate progression-free median survival patient treat neo-adjuvant cisplatin gemcitabine hydrochloride chemotherapy bevacizumab follow radical cystectomy . - Determine feasibility , tolerability toxicity neoadjuvant cisplatin gemcitabine hydrochloride bevacizumab patient muscle invasive , resectable , nonmetastatic transitional cell carcinoma ( TCC ) bladder . - Correlate pT0 cystoscopy pT0 radical cystectomy patient treat neoadjuvant cisplatin gemcitabine hydrochloride chemotherapy bevacizumab patient muscle invasive , resectable , nonmetastatic transitional cell carcinoma ( TCC ) bladder . - Determine influence adjuvant paclitaxel plus bevacizumab ( pathologic non-complete responder ) progression-free overall survival rate . - Determine safety bevacizumab use adjuvant set therapy locally advanced bladder cancer . - Determine rate postoperative complication , follow treatment neoadjuvant therapy ( cisplatin , gemcitabine hydrochloride , bevacizumab ) radical cystectomy . OUTLINE : This multicenter study . - Neoadjuvant therapy : Patients receive cisplatin IV 60 minute bevacizumab IV 30-90 minute day 1 gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Patients nonmetastatic disease 12 week proceed surgery least 30 day later . - Surgery : Patients undergo radical cystectomy . Patients achieve pT0 status ( pathologic complete remission rate , evidence disease cystectomy specimen ) observe study . Patients evidence disease proceed adjuvant therapy . - Adjuvant therapy : Patients receive bevacizumab IV 30-90 minute paclitaxel IV 3 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 6 year . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell cancer ( TCC ) bladder Staged follow : Muscle invasive ( T2T4a ) Node negative ( N0 ) No histologically cytologically proven lymph node metastases Nonmetastatic ( M0 ) No evidence distant metastasis Resectable disease Able begin protocol treatment within 6 week transurethral resection cystoscopic evaluation No central nervous system brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Karnofsky 60100 % White blood cell count ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 AST ( SGOT ) ALT ( SGPT ) ≤ 2 time upper limit normal Bilirubin ≤1.5 mg/dL Creatinine clearance ≥ 60 mL/min Urine protein/creatinine ratio &lt; 1.0 Blood pressure ≤150/100 mm Hg No prohibitive medical risk chemotherapy No history allergic reaction attribute compound similar chemical biologic composition cisplatin , gemcitabine hydrochloride , paclitaxel No unstable angina No history myocardial infarction within past 6 month No cardiac arrhythmias No New York Heart Association ( NYHA ) congestive heart failure ≥ grade 2 No history stroke within past 6 month No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious nonhealing wound , ulcer , bone fracture No psychiatric illness psychosocial situation would limit ability comply study and/or followup procedure Not pregnant nursing Negative pregnancy test Fertile patient must agree use adequate contraception prior study entry duration study participation No significant traumatic injury past 28 day PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy No prior pelvic radiation therapy More 4 week since prior participation experimental drug study Genentechsponsored bevacizumab cancer study No concurrent participation experimental drug study Genentechsponsored bevacizumab cancer study No major surgical procedure open biopsy within past 28 day No anticipation need major surgical procedure course study No minor surgical procedure , fineneedle aspiration , core biopsy within past 7 day No concurrent treatment hormone chemotherapeutic agent except follow : Steroids give adrenal failure Hormones administer nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic solid tumor protocols No concurrent investigational commercial agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>